10-Q: Escalon Medical Corp. Reports Profitable Second Quarter, Revenue Up 3.2%

Escalon Medical Corp. reports increased net revenue and a profitable quarter, driven by growth in Trek's gas products, as detailed in their Form 10-Q filing for the period ended December 31, 2024.

Summary

• Escalon Medical Corp.'s consolidated net revenue increased by approximately $188,000, or 3.2%, reaching $6,002,000 for the six months ended December 31, 2024, compared to the same period last year.
• The increase in net revenue is primarily due to a $358,000 increase in sales of Trek's gas products, offset by a $157,000 decrease in Sonomed's ultrasound products.
• Consolidated cost of goods sold decreased as a percentage of total revenue, from 56.0% to 53.6%, due to changes in product sales mix, geographic differences, inventory valuation adjustments, reduced digital headcount, lower unit fixed costs for Trek, and increased unit prices for Sonomed's surgical products.
• Marketing, general, and administrative expenses decreased by $23,000, or 1.0%, to $2,261,000.
• Research and development expenses decreased by $62,000, or 17.3%, to $297,000.
• The company reported net income of $246,021 for the three months ended December 31, 2024, compared to a net loss of $76,321 for the same period in 2023.
• Basic and diluted net income per share were both $0.02 for the three months ended December 31, 2024, compared to a loss of $0.01 per share for the same period in 2023.
• The company's operations are subject to regulation and inspection by the FDA.
• The company's continuance as a going concern is dependent on its future profitability and on the on-going support of its shareholders, affiliates and creditors.
• The company is actively pursuing business partnerships, managing its continuing operations, and implementing cost-cutting measures to mitigate going concern issues.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook due to increased revenue, profitability, and improved cash flow. However, the going concern warning and identified material weakness in internal control temper the overall sentiment.

Positives

• The company achieved net income of $246,021 for the three months ended December 31, 2024, a significant improvement from the net loss of $76,321 in the same period of the previous year.
• Net revenue increased by 3.2% to $6,002,000 for the six months ended December 31, 2024.
• The company's cash position improved, with approximately $521,000 in cash on hand and $256,000 in restricted cash as of December 31, 2024.
• Working capital increased approximately $365,000 as of December 31, 2024.
• The company provided approximately $334,000 of cash in operating activities during the six months ended December 31, 2024, compared to using approximately $438,000 in the same period last year.

Negatives

• The company has an accumulated deficit of approximately $68.3 million.
• The company's operations have not historically generated sufficient revenues to enable profitability.
• The company's auditor identified a material weakness in internal control related to the proper design and implementation of controls over estimates relating to the valuation of inventory and allowance for doubtful accounts, specifically over the precision of management's review during the year end June 30, 2024.

Risks

• The company's operations are subject to regulation and inspection by the FDA.
• The company's ability to continue as a going concern is dependent on its future profitability and on the on-going support of its shareholders, affiliates and creditors.
• The company may need to raise additional capital or take other actions to fund operations.
• The company is affected by economic, political, and other conditions in the foreign countries in which it does business as well as U.S. laws regulating international trade.
• The company identified a material weakness in internal control related to the proper design and implementation of controls over estimates relating to the valuation of inventory and allowance for doubtful accounts.

Future Outlook

The company expects to continue to fund operations from cash on hand and through capital raising sources if possible and available, which may be dilutive to existing stockholders, through revenues from the licensing of the Company's products, or through strategic alliances.

Management Comments

• The reader is encouraged to read this Form 10-Q in its entirety to gain a more complete understanding of factors impacting Company performance and financial condition.

Industry Context

Escalon Medical Corp. operates in the healthcare market, specializing in ophthalmology, which is subject to stringent regulatory oversight by the FDA. The company competes with other medical device manufacturers and distributors in this space. The reported increase in revenue and profitability suggests the company is navigating the competitive landscape effectively, particularly with its Trek gas products.

Comparison to Industry Standards

• It is difficult to provide a precise comparison to industry standards without specific competitor data.
• However, medical device companies like Alcon, Bausch + Lomb, and Carl Zeiss Meditec operate in similar markets.
• These companies often have higher revenue bases and broader product portfolios.
• Escalon's focus on ophthalmology and niche products like Trek gas products differentiates it, but also presents scalability challenges compared to larger, more diversified competitors.
• The company's ability to improve its cost of goods sold as a percentage of revenue is a positive sign, as efficiency is crucial in the competitive medical device industry.

Legal Proceedings

• The Company, from time to time is involved in various legal proceedings and disputes that arise in the normal course of business.
• These matters have included intellectual property disputes, contract disputes, employment disputes and other matters.
• The Company does not believe that the resolution of any of these matters has had or is likely to have a material adverse impact on the Company's business, financial condition or results of operations.

Related Party Transactions

• As of December 31, 2024, and 2023, the related party interest accrual of $112,389 related to the debt prior to the exchange, remained as an on demanded payable.
• On February 14, 2018, the Company entered into a Debt Exchange Agreement (the Exchange Agreement) with Richard DePiano, Sr., (Mr. DePiano Sr.), the Company's former Chairman and DP Associates Inc. Profit-Sharing Plan of which Mr. DePiano Sr. is the sole owner and sole trustee (the Holders).
• Pursuant to the terms of the Exchange Agreement, effective February 15, 2018, the Holders exchanged a total of $645,000 principal amount of debt related to the accounts receivable factoring program the Company owes the Holders for 2,000,000 shares of Series A Convertible Preferred Stock (the Preferred Stock).
• Each share of Preferred Stock entitles the Holder thereof to 13 votes per share and will vote together with all other classes and series of stock of the Company as a single class on all actions to be taken by the Company's stockholders.
• As a result of this voting power, the Holders as of December 31, 2024 beneficially own approximately 77.81% of the voting power on all actions to be taken by the Company's shareholders.
• Subject to the terms and conditions of Preferred Stock, the holder of any share or shares of the Preferred Stock has the right, at its option at any time, to convert each such share of Preferred Stock (except that, upon any liquidation of the Company, the right of conversion will terminate at the close of business on the business day fixed for payment of the amounts distributable on the Preferred Stock) into 2.15 shares of Common Stock (the Conversion Ratio).
• The Conversion Ratio is subject to standard provisions for adjustment in the event of a subdivision or combination of the Company's Common Stock and upon any reorganization or reclassification of the capital stock of the Company.
• If the Holders were to convert their shares of Preferred Stock into Common Stock at the Conversion Ratio the Holders would receive a total of 4,300,000 shares of Common Stock, or approximately 36.70% of the then outstanding shares of Common Stock assuming such conversion.
• Each outstanding share of the Preferred Stock accrues dividends calculated cumulatively at the annual rate of $.0258 per share (such amount subject to equitable adjustment in the event of any stock dividend, stock split, combination, reclassification other similar event), payable upon the earlier of (i) a liquidation, dissolution or winding up of the Company or (ii) conversion of the Preferred Stock into Common Stock.
• Upon either of such events, all such accrued and unpaid dividends, whether or not earned or declared, to and until the date of such event, will become immediately due and payable and will be paid in full.
• The dividends payable to the holders of the Preferred Stock is payable in cash or, at the election of any such holder, in a number of additional shares of Common Stock equal to the amount of the dividend expressed in dollars divided by the then applicable Conversion Ratio, described above.
• As of December 31, 2024, and June 30, 2024 , the cumulative dividends payable are $354,943 ($0.1775 per share) and $329,003 ($0.1645 per share), respectively.
• Mr. DePiano Sr. passed away on October 3, 2019, and left a will by which he appointed Richard J. DePiano, Jr., the Chief Executive Officer of the Company, as executor.
• Richard DePiano Jr. was elected to serve as Chairman of the Company's board.
• Mr. DePiano, Jr. qualified as executor and has control over the listed shares in his capacity as executor of Mr. DePiano Sr.'s estate.

Stakeholder Impact

• Shareholders: The improved financial performance is generally positive for shareholders, but the going concern warning and potential dilution from future capital raises are concerns.
• Employees: Improved financial stability could lead to greater job security and potential for future growth.
• Customers: Consistent product quality and service are expected.
• Suppliers: Timely payments and continued business relationships are expected.
• Creditors: The company's ability to meet its debt obligations is crucial.

Next Steps

• The company will continue to monitor costs and expenses closely.
• The company may need to raise additional capital or take other actions to fund operations.
• The company expects to continue to fund operations from cash on hand and through capital raising sources if possible and available, which may be dilutive to existing stockholders, through revenues from the licensing of the Company's products, or through strategic alliances.
• The company may seek to sell additional equity or debt securities through one or more discrete transactions, or enter a strategic alliance arrangement.

Key Dates